MKS Inc. (MKSI) Market Cap & Valuation Ratios
MKS Inc. (MKSI) has a market cap of $13.3B, a trailing P/E of 31.3 and a price-to-sales ratio of 3.1, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MKSIMKS Inc.Follow MKSI — free
—
Price chart with a free account
- Market cap
- 13.3B
- P/E TTM
- 31.3
- Dividend yield
- 0.5%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
scientific & technical instruments · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| MKSI | 13 | 31.3 | 3.9 | 16.4 | 3.4% | +16% | 16% | 9% |
| TDY | 29 | 28.6 | 4.6 | 18.4 | 4.0% | +9% | 20% | 8% |
| FTV | 18 | 35.7 | 4.9 | 18.1 | 5.2% | +6% | 18% | 6% |
| TRMB | 15 | — | 4.2 | 19.0 | 5.2% | +6% | 17% | 8% |
| NVMI | 9.9 | 39.1 | 10.8 | 36.6 | 2.2% | +16% | 29% | 12% |
| CGNX | 9.3 | 53.4 | 8.2 | 33.4 | 2.9% | +17% | 22% | 12% |
| ESE | 6.0 | — | 4.7 | 24.6 | 3.3% | +27% | 16% | 8% |
| ST | 5.9 | 67.3 | 2.1 | 15.1 | 9.9% | +0.8% | 8% | 3% |
| CAMT | 5.5 | 115.7 | 10.6 | 41.3 | 2.3% | +12% | 26% | 13% |
| NOVT | 5.3 | 89.7 | 4.7 | 31.4 | 2.1% | +8% | 9% | 6% |
| VNT | 4.6 | 14.2 | 2.0 | 10.0 | 8.3% | +0.9% | 19% | 16% |
| Median of these 10 | 46.3 | 4.7 | 21.8 | 3.6% | +8% | 19% | 8% |
P/E 31.3 vs. a peer median of 46.3; EV/Sales 3.9 vs. 4.7. MKSI's own P/E sits at the 50th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesTRMB and ESE have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
MKS Inc. — questions
- What is MKS Inc.'s market cap?
- $13.3B.
- What is MKS Inc.'s P/E ratio?
- 31.3 on trailing twelve-month earnings to 2026-06-30.
- What is MKS Inc.'s price-to-sales ratio?
- 3.1.
Every figure on this page comes from MKS Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.